Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Pembrolizumab in advanced clear cell RCC
McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.
Key clinical point: Pembrolizumab monotherapy shows promising efficacy and tolerability in (accRCC).
Major finding: Overall response rate was 38%.
Study details: The phase 2 KEYNOTE-427 trial of 110 patients from one of two study cohorts.
Disclosures: Merck sponsored the study. Dr. McDermott reported consulting or advisory roles with Array BioPharma, Bristol-Myers Squibb, Exelixis, Genentech/Roche, Merck, Novartis, Pfizer, and X4 Pharma. His institution has received research funding from Prometheus Laboratories.
Source: McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.
McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.